Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (DE:RV7)
FRANKFURT:RV7
Halozyme (RV7) Stock Price & Analysis
0 Followers
RV7 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€27.43 - €55.37
Previous Close€37
Volume0.00
Average Volume (3M)138.00
Market Cap
€4.92B
Enterprise Value€5.86B
Total Cash (Recent Filing)$483.28M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)N/A
Beta0.39
Next Earnings
Feb 20, 2024EPS Estimate
€0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding132,098,110
10 Day Avg. Volume0
30 Day Avg. Volume138
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-8.02
Price to Sales (P/S)7.38
Price to Cash Flow (P/CF)10.00
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.51
Enterprise Value/Gross Profit11.26
Enterprise Value/Ebitda14.42
Forecast
1Y Price Target
€47.80Price Target Upside29.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Halozyme News
Pre-EarningsHALO Upcoming Earnings Report: What to Expect?
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
24.21% Other Institutional Investors
75.79% Public Companies and
Individual Investors
RV7 FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was €27.43 and its highest was €55.37 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Currently, no data Available
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Feb 20, 2024 which is in 72 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Nov 06, 2023. The company reported €0.695 earnings per share for the quarter, beating the consensus estimate of €0.654 by €0.041.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is €0.71.
How many shares outstanding does Halozyme Therapeutics have?
Currently, no data Available
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of €0.695 in its last earnings report, beating expectations of €0.654. Following the earnings report the stock price went down -0.879%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Among the largest hedge funds holding Halozyme Therapeutics’s share is Driehaus Capital Management LLC. It holds Halozyme Therapeutics’s shares valued at 20M.
---
Halozyme Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€47.80 (29.20% Upside)
€47.80 (29.20% Upside)
Blogger Sentiment
Bullish
DE:RV7 Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Positive
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.46%
12-Months-Change
Fundamentals
Return on Equity
146.69%
Trailing 12-Months
Asset Growth
1.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
---